BioXcel Therapeutics found using ticker (BTAI) now have 10 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 185 and 68 with a mean TP of 112. Now with the previous closing price of 56.98 this would indicate that there is a potential upside of 96.6%. There is a 50 day moving average of 53.6 while the 200 day moving average is 48.33. The company has a market cap of $1,344m. Find out more information at: http://www.bioxceltherapeutics.com
BioXcel Therapeutics, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics has a collaboration with Merck KGaA; Nektar Therapeutics; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics is a subsidiary of BioXcel Corporation.